2012 AZBio Fast Lane Award Winner - Ulthera
Beauty and Growth – Ulthera, Inc Ulthera’s mission is to work with physicians to provide therapeutic ultrasound to improve the appearance and health of patients worldwide. The company is not only defined by its proprietary technology, but also its people. Ulthera’s team consists of experts in their respective fields who are aligned by the strength of the company’s mission and its leadership. Ulthera was founded in 2004 to leverage seven years of prior scientific research in therapeutic ultrasound for aesthetic and medical applications. In 2009, the Ulthera® System received FDA approval in the United States and is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive treatment of the face to achieve a brow lift. Ulthera’s robust scientific foundation and relentless pursuit of superior clinical outcomes have resulted in the rapid global uptake of the Ulthera platform. As Ulthera continues to develop and provide more applications for its platform, the company also remains committed to bringing value to physicians and their patients. In 2006, Matt Likens was hired as President and CEO of Ulthera by founder and owner Michael Slayton, Ph. D, with the expectation of obtaining FDA approval for Ulthera’s product and service (known as Ultherapy) within three months. Less than two years into his tenure at Ulthera, Matt found himself navigating this venture capital backed start-up though the worst economic downtown since the Great Depression. The Company also found itself facing an increasing skeptical and less commercially friendly US Food and Drug Administration (FDA) regime. With both of these risks significantly threatening the Company’s viability, Matt decided to change the Company’s regulatory pathway and focus by obtaining CE Mark from the European Union prior to obtaining FDA clearance. If this bet paid off, Ulthera’s regulatory runway would be significantly reduced and the Company would be able to generate sales in the European market. These revenues would also allow the Company to lessen the need to obtain additional venture capital financing thus reducing additional dilution to the Company’s current shareholders. While risky, the core of this decision was based on the multinational experience Likens attained at Baxter and his general entrepreneurial nature. The bet ultimately paid off. Today, Ulthera is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. More than 1,000 Ulthera Systems have been sold globally while treatments performed using the System have surpassed 100,000.
Flagship Biosciences - AZBio Company of the Year | 2012 Finalist
Flagship Biosciences provides quantitative tissue analysis services for pharmaceutical and medical device development. Flagship offers a broad range of tissue assessment options, achieved through a diverse set of approaches. Flagship Biosciences provides tissue analysis solutions to over sixty biotech, pharmaceutical, and medical device clients, with global programs in place for tissue-based companion diagnostics with three of the largest pharmaceutical companies in the world. Their sales grew 400% in 2011, and are on track to triple again in 2012. Flagship scientists published seven peer-reviewed articles in 2011, and filed 4 patent applications during the year. However, the largest development for Flagship was the acquisition of a histology and immunohistochemistry laboratory during the close 2011 which has added tissue procurement to complete their tissue-based analysis operations. Finally, the company’s image analysis technology won a best poster award at the Pathology Visions 2011 conference in San Diego, and a best presentation award at the Pathology Informatics 2011 meeting in Pittsburgh The company is currently working on a medical device spinout of their existing operations and expansion into Phoenix later this year. Committed to growing not only the company but also Arizona’s bioscience talent pool, the company currently utilizes many students from Northern Arizona University. Flagship Biosciences was honored in 2011 with the 2011 AZBio Fast Lane Award .
Company Presentation: Invoy Technologies, LLC
Exhaled Breath: A Portal for Pain-Free Biochemical Analysis Invoy is engaged in the development and commercialization of breath analysis devices for a broad range of applications. Invoy plans to offer patients the ability to monitor their health in the convenience of their own home – with a prescription-based breath analysis device called the Voyager. The process is pain-free and the results are quick and accurate; giving patients peace of mind and confidence in using this new-to-the-market device.
UA College of Medicine Phoenix | 2013 Commencement
2013 Commencement UA College of Medicine – Phoenix Fifty University of Arizona College of Medicine -- Phoenix medical students were officially conferred with their medical degrees at ceremonies on May 8 in the third graduation for the downtown Phoenix medical school. Read more: http://phoenixmed.arizona.edu
John W. Lewis, Mayor of the Town of Gibert - 2013 Public Service Award Honoree
John W. Lewis, Mayor of the Town of Gilbert,was recognized with the 2013 AZBio Public Service Award from the Arizona Bioindustry Association in recognition for his vision and leadership in creating a health and bioscience innovation strategic focus in America’s largest town. Under Mayor Lewis’s leadership, Gilbert is attracting global leaders, spurring economic development, and creating quality and high-wage life science jobs.
Company Presentation - Kulira Technologies
Kulira Technologies is an advanced biomedical engineering company that designs solutions for surgical oncology using state-of-the-art biomaterials. President and CEO, Xenia Kachur, shares where they've been and where they are going at AZBio Expo 2013.